Semaglutide 2.4 mg Gets US Approval for Fatty Liver Disease With Fibrosis | Research

The takeaway

Semaglutide 2.4 mg/week received accelerated US approval for MASH with significant fibrosis, based on trials showing improvements in steatosis, disease resolution, and fibrosis reduction.

First effective MASH drug
Semaglutide 2.4 mg/week is among the first medications to receive US approval for metabolic liver disease with fibrosis

What the researchers found

Semaglutide 2.4 mg/week achieved significant improvements in hepatic steatosis, MASH resolution, and fibrosis reduction in phase 2 and 3 trials, leading to conditional US approval.

Why it matters

MASH is the most common cause of liver transplantation and had no effective pharmacological treatment until now. Semaglutide's approval changes the treatment landscape for millions of patients with fatty liver disease.

The numbers in context

Semaglutide 2.4 mg/week SC. Conditional accelerated approval for MASH with F2/F3 fibrosis. Phase 2-3 data show MASH resolution and fibrosis improvement. Consistent cardiovascular and renal benefits.

How the study worked

Focused review of phase 2 and 3 clinical trial data supporting the accelerated US approval of semaglutide 2.4 mg/week for MASH with fibrosis.

Who was studied

Adults with MASH and significant fibrosis

What this study cannot tell us

Conditional accelerated approval requires confirmatory trials. Long-term effects on cirrhosis prevention and liver cancer risk reduction are not yet established.

How to read the evidence

Based on phase 2 and 3 clinical trials supporting FDA accelerated approval — strong evidence but confirmatory long-term trials are required.

When this study was published

Published in 2025, covering the most recent clinical trial data and regulatory approval.

The bigger picture

This approval marks the beginning of a new era in liver disease treatment, where metabolic drugs address the root causes of fatty liver disease rather than just managing complications.

Questions still open

Will semaglutide prevent progression to cirrhosis in long-term use?
How will this approval affect clinical practice guidelines for MASH management?

Common questions

Can semaglutide treat fatty liver disease?

Yes, semaglutide 2.4 mg weekly has received accelerated US approval for MASH (the inflammatory form of fatty liver disease) with significant fibrosis. Clinical trials showed it can reduce liver fat, resolve liver inflammation, and improve fibrosis.

What is MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is the new name for what was previously called NASH. It is the inflammatory form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure if untreated.

Read the original research

Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

Liver international : official journal of the International Association for the Study of the Liver, 45(11), e70407

View on PubMed ↗Publisher’s paper ↗

Citation

Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia; Zheng, Ming-Hua; Aghemo, Alessio; Valenti, Luca. (2025). Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.. Liver international : official journal of the International Association for the Study of the Liver, 45(11), e70407. https://doi.org/10.1111/liv.70407